Cargando…

Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation

This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th–17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual’s immune system to fight the tumour. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Cairns, Linda, Aspeslagh, Sandrine, Anichini, Andrea, Kyte, Jon Amund, Blank, Christian, Ascierto, Paolo, Rekers, Nicolle, Straten, Per Thor, Awada, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130327/
https://www.ncbi.nlm.nih.gov/pubmed/27994647
http://dx.doi.org/10.3332/ecancer.2016.691
_version_ 1782470713957941248
author Cairns, Linda
Aspeslagh, Sandrine
Anichini, Andrea
Kyte, Jon Amund
Blank, Christian
Ascierto, Paolo
Rekers, Nicolle
Straten, Per Thor
Awada, Ahmad
author_facet Cairns, Linda
Aspeslagh, Sandrine
Anichini, Andrea
Kyte, Jon Amund
Blank, Christian
Ascierto, Paolo
Rekers, Nicolle
Straten, Per Thor
Awada, Ahmad
author_sort Cairns, Linda
collection PubMed
description This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th–17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual’s immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.
format Online
Article
Text
id pubmed-5130327
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-51303272016-12-19 Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation Cairns, Linda Aspeslagh, Sandrine Anichini, Andrea Kyte, Jon Amund Blank, Christian Ascierto, Paolo Rekers, Nicolle Straten, Per Thor Awada, Ahmad Ecancermedicalscience Conference Report This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th–17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual’s immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present. Cancer Intelligence 2016-11-10 /pmc/articles/PMC5130327/ /pubmed/27994647 http://dx.doi.org/10.3332/ecancer.2016.691 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Report
Cairns, Linda
Aspeslagh, Sandrine
Anichini, Andrea
Kyte, Jon Amund
Blank, Christian
Ascierto, Paolo
Rekers, Nicolle
Straten, Per Thor
Awada, Ahmad
Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
title Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
title_full Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
title_fullStr Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
title_full_unstemmed Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
title_short Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
title_sort cancer immunotherapy: from the lab to clinical applications—potential impact on cancer centres’ organisation
topic Conference Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130327/
https://www.ncbi.nlm.nih.gov/pubmed/27994647
http://dx.doi.org/10.3332/ecancer.2016.691
work_keys_str_mv AT cairnslinda cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT aspeslaghsandrine cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT anichiniandrea cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT kytejonamund cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT blankchristian cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT asciertopaolo cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT rekersnicolle cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT stratenperthor cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation
AT awadaahmad cancerimmunotherapyfromthelabtoclinicalapplicationspotentialimpactoncancercentresorganisation